SAB Biotherapeutics, Inc. (SABS)
NASDAQ: SABS · Real-Time Price · USD
1.370
+0.070 (5.38%)
Apr 23, 2025, 4:00 PM EDT - Market closed
SAB Biotherapeutics Stock Forecast
SABS's stock price has decreased by -68.79% in the past year and price targets may not have had time to catch up.
Stock Price Forecast
The 5 analysts with 12-month price forecasts for SAB Biotherapeutics stock have an average target of 11.4, with a low estimate of 6.00 and a high estimate of 20. The average target predicts an increase of 732.12% from the current stock price of 1.37.
Analyst Consensus: Strong Buy
Analyst Ratings
The average analyst rating for SAB Biotherapeutics stock from 5 stock analysts is "Strong Buy". This means that analysts believe this stock is likely to perform very well in the near future and significantly outperform the market.
Recommendation Trends
| Rating | Nov '24 | Dec '24 | Jan '25 | Feb '25 | Mar '25 | Apr '25 |
|---|---|---|---|---|---|---|
| Strong Buy | 4 | 4 | 4 | 4 | 4 | 4 |
| Buy | 1 | 1 | 1 | 1 | 1 | 1 |
| Hold | 0 | 0 | 0 | 0 | 0 | 0 |
| Sell | 0 | 0 | 0 | 0 | 0 | 0 |
| Strong Sell | 0 | 0 | 0 | 0 | 0 | 0 |
| Total | 5 | 5 | 5 | 5 | 5 | 5 |
Latest Forecasts
| Analyst | Firm | Rating | Rating | Action | Price Target | Upside | Date |
|---|---|---|---|---|---|---|---|
| Chardan Capital | Chardan Capital | Strong Buy Maintains $25 → $20 | Strong Buy | Maintains | $25 → $20 | +1,359.85% | Apr 1, 2025 |
| HC Wainwright & Co. | HC Wainwright & Co. | Strong Buy Reiterates $6 | Strong Buy | Reiterates | $6 | +337.96% | Apr 1, 2025 |
| Chardan Capital | Chardan Capital | Strong Buy Maintains $25 | Strong Buy | Maintains | $25 | +1,724.82% | Jan 29, 2025 |
| HC Wainwright & Co. | HC Wainwright & Co. | Strong Buy Reiterates $6 | Strong Buy | Reiterates | $6 | +337.96% | Jan 29, 2025 |
| Chardan Capital | Chardan Capital | Strong Buy Maintains $25 | Strong Buy | Maintains | $25 | +1,724.82% | Nov 7, 2024 |
Financial Forecast
Revenue This Year
680.00K
from 1.32M
Decreased by -48.58%
Revenue Next Year
1.02M
from 680.00K
Increased by 50.00%
EPS This Year
-3.05
from -3.68
EPS Next Year
-2.89
from -3.05
Historical EPS numbers are GAAP, while forecasted numbers may be non-GAAP.
Revenue Forecast
| Revenue | 2025 | 2026 | 2027 | 2028 | 2029 |
|---|---|---|---|---|---|
| High | 2.1M | 3.2M | 3.7M | ||
| Avg | 680,003 | 1.0M | 1.8M | ||
| Low | n/a | n/a | n/a |
Revenue Growth
| Revenue Growth | 2025 | 2026 | 2027 | 2028 | 2029 |
|---|---|---|---|---|---|
| High | 58.8% | 363.2% | 260.3% | ||
| Avg | -48.6% | 50.0% | 75.0% | ||
| Low | - | - | - |
EPS Forecast
| EPS | 2025 | 2026 |
|---|---|---|
| High | -1.02 | -1.04 |
| Avg | -3.05 | -2.89 |
| Low | -5.20 | -3.95 |
EPS Growth
| EPS Growth | 2025 | 2026 |
|---|---|---|
| High | - | - |
| Avg | - | - |
| Low | - | - |
Sources: Price targets and analyst ratings provided by Benzinga. Revenue and EPS forecast data provided by Finnhub. The data is sourced from Wall Street analysts. Data disclaimer.